Product Description
Ponesimod is an orally active, selective S1P1R modulator that causes dose-dependent sequestration of lymphocytes in lymphoid organs. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26770667/)
Mechanisms of Action: S1P1 Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Chile | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States
Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting
Known Adverse Events: Hypertension | Respiratory Tract Infections
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belarus, Belgium, Bosnia, Bulgaria, Canada, Croatia, Czech Republic, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PIONEER | P3 |
Active, not recruiting |
Multiple Sclerosis, Relapsing-Remitting |
2027-10-27 |
|
| OPTIMUM-LT | P3 |
Completed |
Multiple Sclerosis |
2024-01-16 |
|
| OPTIMUM LT | P3 |
Active, not recruiting |
Multiple Sclerosis |
2024-01-04 |
|
| 2009-011470-15 | P2 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2023-12-29 |